QuantHealth, an Israeli startup that offers an AI-powered clinical trial design, raised $15 million in a Series A financing round co-led by Bertelsmann Investments and Pitango HealthTech.
Founded in 2020, QuantHealth is an AI company conducting patient-centric drug simulations to accelerate and de-risk drug development. Over 90% of drugs in clinical development stage fail to reach the market, which accumulates to a $45B/year direct lost to the pharma and biotech industry.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Today, over 90% of experimental therapies that reach human trials fail to make it to market. These trials fail primarily due to lack of efficacy and safety. Some drugs shouldn’t go to trial, while many that do are suboptimally designed. All this is causing trials to become increasingly longer, more expensive, and less effective while patients aren’t getting the drugs they need.
QuantHealth boasts that its platform allows their pharma and biotech partners to rapidly run thousands of variations of their clinical trials to optimize the trial design and significantly increase the probability of trial success, all while enabling discovery of new clinical opportunities and optimization strategies. QuantHealth says that it offers one the largest integrated datasets that spans the clinical, pharmacological and biological domains together with a proprietary AI platform that can “predict patient-response to both approved and novel therapies.”
“According to a recent Deloitte article, ROI on pharma R&D has steadily declined, reaching 1.2 percent in 2022, the lowest the industry has seen in decades,” said Orr Inbar, CEO and Co-Founder of QuantHealth. “This decline is happening at a time when the need for efficient drug development has never been greater. We firmly believe that deep AI solutions like ours will dramatically enhance the success of clinical trials, and pave the way towards better and cheaper therapies for patients around the world.”
In other QuantHealth news, the Israeli startup was accepted to join Avicenna Alliance, a global non profit organization based in Brussels, as a member. Avicenna advocates for the regulation and deployment of computer modeling and simulation (also known as in silico methods). The Avicenna Alliance’s mission aims to complement traditional methods (bench, animal and clinical testing and trials) to deliver faster safer and more affordable health care to the patient.
